- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04604600
Multimodal Biomarkers for Diagnosis and Prognosis in VCI (VCI)
Multimodal Biomarkers for Diagnosis and Prognosis in Vascular Cognitive Impairment
We will try to
- establish the correlation of plasma Aβ40 and Aβ42 level, ApoE genotype, MRI imaging markers in the diagnosis and prognosis of VCI patients
- understand more on the pathophysiology of VCI.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Background and objectives Owing to the aging problem, cognitive impairment has been a worldwide health issue. Vascular cognitive impairment (VCI) and Alzheimer's disease (AD) are the two most common causes. It has been reported that VCI and AD share many common risk factors. MRI is essential in assessing the extent, location and type of vascular lesions. Amyloid PET has been used in detecting cerebral amyloid burden non-invasively since 2004. There are only small number of studies using amyloid PET in VCI and the results are still controversial. In the current proposal, we will investigate
- the correlation of clinical risk factors, ApoE genotype, various MRI markers, and amyloid PET expression
- assess the influence of ApoE genotype on different biomarkers, including MRI markers, amyloid retention, and plasma Aβ40 and Aβ42 levels
- the potential of amyloid PET as a prognostic factor for VCI patients.
Materials and methods This study will be conducted in National Taiwan University Hospital and Bei-Hu Branch Hospital. Sixty clinical diagnosed VCI, 30 AD patients and 30 normal subjects will be enrolled in this 3-year prospective study. We will collect vascular risk factors, neuropsychological tests, 10 cc venous blood for plasma Aβ40, Aβ42, total tau and phosphorylated level measurement by IMR assay, ApoE genotype, brain MRI, and amyloid PET of each patient and control subject. All the data will be analyzed together.
Expected Results We will try to
- establish the correlation of plasma Aβ40 and Aβ42 level, ApoE genotype, MRI imaging markers in the diagnosis and prognosis of VCI patients
- understand more on the pathophysiology of VCI.
Studietype
Inschrijving (Verwacht)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Taipei, Taiwan, 100
- Werving
- National Taiwan Univeristy Hospital
-
Contact:
- Yen Ruoh Fang, MD, PhD
- Telefoonnummer: 65581 886-2-23123456
- E-mail: rfyen@ntu.edu.tw
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
I. Vascular cognitive impairment patients:
- Age older than 20 years.
Clinical diagnosis:
- At least one obstacle to executive function, attention, memory, language and visual space function.
- Affected activities of daily living.
- Brain MRI showing cerebrovascular disease.
- Patient agrees to participate in the study and is willing to receive 11C-PiB PET.
II. Alzheimer's disease (AD) patients:
- Age older than 20 years.
Clinical diagnosis:
- Amnesia or non-amnesia (language, visual space, executive ability) performance.
- Affected activities of daily living.
- Patient agrees to participate in the study and is willing to receive 11C-PiB PET.
III. Normal controls:
- Age older than 20 years.
- No neurological or psychiatric history.
- Patient agrees to participate in the study and is willing to receive 11C-PiB PET.
Exclusion Criteria:
-
I. Vascular cognitive impairment patients:
- Have other illnesses, including people with drug / alcohol abuse / addictivity within three months.
- Patient cannot accept brain magnetic resonance imaging or 11C-PiB PET, such as agitation and inability to cooperate, allergy to contrast agents, hemodynamic instability (blood pressure, pulse, or blood oxygen is not in the normal range), and a heart rhythm regulator has been implanted , Have ever undergone intracranial aneurysm clamp surgery, claustrophobia and hemodynamic instability.
- Pregnant woman or intends to be pregnant in the near future.
- Patient who is breast feeding or intends to.
- Allergic to 11C-PiB, or with severe drug allergy history.
- Patient or the family refuses to participate in the study.
II. Alzheimer's disease (AD) patients:
Have other illnesses, including:
- Cognitive disorders caused by cerebrovascular diseases (the decline in cognitive function is closely related to the time of stroke, multiple large-scale necrosis, and severe white matter lesions).
- The main manifestation of dementia is Lewy body dementia
- Symptoms are behavioral variation of frontotemporal dementia.
- The symptoms are obviously semantic progressive aphasia.
- Symptoms are not fluent in primary progressive aphasia.
- Other comorbidities that affect cognitive function (including other active neurological diseases, or non-neurological diseases but the disease or the treatment used will affect cognitive function)
- Patient cannot accept brain magnetic resonance imaging or 11C-PiB PET, such as agitation and inability to cooperate, allergy to contrast agents, hemodynamic instability (blood pressure, pulse, or blood oxygen is not in the normal range), and a heart rhythm regulator has been implanted , Have ever undergone intracranial aneurysm clamp surgery, claustrophobia and hemodynamic instability.
- Pregnant woman or intends to be pregnant in the near future.
- Patient who is breast feeding or intends to.
- Allergic to 11C-PiB, or with severe drug allergy history.
- Patient or the family refuses to participate in the study.
III. Normal controls:
- Patient cannot accept brain magnetic resonance imaging or 11C-PiB PET, such as agitation and inability to cooperate, allergy to contrast agents, hemodynamic instability (blood pressure, pulse, or blood oxygen is not in the normal range), and a heart rhythm regulator has been implanted , Have ever undergone intracranial aneurysm clamp surgery, claustrophobia and hemodynamic instability.
- Pregnant woman or intends to be pregnant in the near future.
- Patient who is breast feeding or intends to.
- Allergic to 11C-PiB, or with severe drug allergy history.
- Patient or the family refuses to participate in the study.
- high risk as assessed by a doctor.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: amyloïde PET, T807 PET
PET/CT
|
Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
PET-beeldvorming
Tijdsspanne: binnen 3 dagen
|
PET-gegevens worden gereconstrueerd met geordende ingestelde verwachtingsmaximalisatie, gecorrigeerd voor verzwakking, en elk frame wordt geëvalueerd om adequate telstatistieken en afwezigheid van hoofdbeweging te verifiëren.
|
binnen 3 dagen
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 201912098MINB
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .